Mukka Proteins Re-appoints 6 Directors, Including MD & CEO, for 5-Year Terms
Mukka Proteins Limited's Board approved the re-appointment of six directors, including MD & CEO Mr. Kalandan Mohammed Haris. Three Independent Directors and three Whole-Time Directors will serve for five-year terms starting January 2027. These appointments are subject to shareholder approval at the upcoming 16th AGM.
The re-appointment of key leadership positions for a significant term of five years provides a sense of stability and continuity for the company's strategic direction. This is likely to be viewed as a positive development, but its immediate impact on financial performance is not directly quantifiable from this announcement alone.
The re-appointment of key managerial personnel and independent directors for extended terms indicates stability and confidence in the existing leadership, which is generally viewed positively by the market.
Mukka Proteins Limited announced significant changes in its directorate following a Board meeting held on Wednesday, 12th August 2026. Basis the recommendations of the Nomination and Remuneration Committee, the Board approved the re-appointment of several key personnel, subject to shareholder approval at the upcoming 16th Annual General Meeting (AGM).
Three Non-Executive Independent Directors have been re-appointed for a second term of five consecutive years, commencing from 15th January 2027 to 14th January 2032. These include Mr. Karkala Shankar Balachandra Rao (DIN: 03589394), Mr. Hamad Bava (DIN: 09448423), and Mr. Narendra Surendra Kamath (DIN: 07255904). All three are not liable to retire by rotation.
Furthermore, the re-appointment of key managerial personnel was approved. Mr. Kalandan Mohammed Haris (DIN: 03020471) will continue as Managing Director and Chief Executive Officer for a further period of five years, effective from 20th January 2027 to 19th January 2032. His office as Managing Director will not be liable to retire by rotation.
Mr. Kalandan Mohammed Althaf (DIN:03051103) has been re-appointed as Whole-Time Director and Chief Financial Officer for a five-year term, also from 20th January 2027 to 19th January 2032. Similarly, Mr. Kalandan Mohammad Arif (DIN:03020564) will continue as Whole-Time Director and Chief Operating Officer for the same five-year period, commencing from 20th January 2027 to 19th January 2032. Their offices as Directors will be liable to retire by rotation.
The detailed disclosures, as required by SEBI circulars, have been provided in Annexures I and II. The Board meeting commenced at 3:30 p.m. and concluded at 4:15 p.m.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.